Company news
Protagonist Therapeutics, Inc. news in 2020
Protagonist Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
December 15, 2020
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
December 14, 2020
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
December 9, 2020
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
December 9, 2020
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories
December 6, 2020
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
December 5, 2020
Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera
December 1, 2020
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020
November 29, 2020
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference
November 24, 2020
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference
November 10, 2020
Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting
November 3, 2020
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
November 3, 2020
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
October 28, 2020
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
October 20, 2020
Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020
September 16, 2020
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
September 9, 2020
Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar
September 1, 2020
Protagonist Appoints Sarah O'Dowd to Board of Directors
August 12, 2020
Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
August 5, 2020
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
June 16, 2020
Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference
June 15, 2020
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress
June 3, 2020
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
May 27, 2020
Protagonist Therapeutics, Inc. Announces Upsizing and Pricing of Underwritten Public Offering of 7,000,000 Shares of Common Stock
May 11, 2020
Protagonist Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Common Stock
May 10, 2020
Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
May 6, 2020
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
May 6, 2020
Protagonist Therapeutics to Announce First Quarter 2020 Financial Results and Provide Corporate and R&D Update
May 3, 2020
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
March 9, 2020
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results
March 1, 2020
Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York
February 18, 2020
Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)
February 6, 2020
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
January 6, 2020
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
January 5, 2020
Decks in 2020
- Corporate Update (September 2020)
Corporate update · 52 slides · Sep 11, 2020